BACKGROUND: Hepatocellular carcinoma (HCC) is a common cancer in certain portions of the world. Currently no effective therapies exist for patients with advanced or metastatic HCC. KW-2189, a DNA minor groove-binding agent, has shown promising activity against HCC in preclinical evaluations. METHODS: A phase II study was conducted to evaluate the activity of KW-2189 in patients with histologic or cytologic confirmed advanced or metastatic HCC who had no prior systemic therapy. Patients received KW-2189 at a dose of 0.5 mg/m2 administered on day 1 of a 6-week cycle. The primary endpoint of the trial was objective regression. Other endpoints included toxicity, disease-free survival, and overall survival. RESULTS: Due to hematologic toxicity the dose of KW-2189 was reduced to 0.375 mg/m2 after 11 patients had been enrolled into the trial. Due to continued significant hematologic toxicity in the next five patients enrolled at the lower dose the trial was closed to accrual. Two responses were seen in patients enrolled at the higher dose, including one sustained CR. CONCLUSION: KW-2189 showed evidence of anti-tumor activity in HCC. However, because of significant and prolonged hematologic toxicity, when given as a single dose every 6 weeks, further development of this drug in HCC is not possible. Further exploration of DNA minor groove-binding agents in the treatment of HCC appears warranted.
BACKGROUND:Hepatocellular carcinoma (HCC) is a common cancer in certain portions of the world. Currently no effective therapies exist for patients with advanced or metastatic HCC. KW-2189, a DNA minor groove-binding agent, has shown promising activity against HCC in preclinical evaluations. METHODS: A phase II study was conducted to evaluate the activity of KW-2189 in patients with histologic or cytologic confirmed advanced or metastatic HCC who had no prior systemic therapy. Patients received KW-2189 at a dose of 0.5 mg/m2 administered on day 1 of a 6-week cycle. The primary endpoint of the trial was objective regression. Other endpoints included toxicity, disease-free survival, and overall survival. RESULTS: Due to hematologic toxicity the dose of KW-2189 was reduced to 0.375 mg/m2 after 11 patients had been enrolled into the trial. Due to continued significant hematologic toxicity in the next five patients enrolled at the lower dose the trial was closed to accrual. Two responses were seen in patients enrolled at the higher dose, including one sustained CR. CONCLUSION: KW-2189 showed evidence of anti-tumor activity in HCC. However, because of significant and prolonged hematologic toxicity, when given as a single dose every 6 weeks, further development of this drug in HCC is not possible. Further exploration of DNA minor groove-binding agents in the treatment of HCC appears warranted.
Authors: M Ichimura; T Ogawa; K Takahashi; E Kobayashi; I Kawamoto; T Yasuzawa; I Takahashi; H Nakano Journal: J Antibiot (Tokyo) Date: 1990-08 Impact factor: 2.649
Authors: E J Small; R Figlin; D Petrylak; D J Vaughn; O Sartor; I Horak; R Pincus; A Kremer; C Bowden Journal: Invest New Drugs Date: 2000-05 Impact factor: 3.850
Authors: O van Tellingen; C J Punt; A Awada; D J Wagener; M J Piccart; Y Groot; L J Schaaf; R E Henrar; W J Nooijen; J H Beijnen Journal: Cancer Chemother Pharmacol Date: 1998 Impact factor: 3.333
Authors: B J Foster; P M LoRusso; E Poplin; M Zalupski; M Valdivieso; A Wozniak; L Flaherty; D A Kasunic; R H Earhart; L H Baker Journal: Invest New Drugs Date: 1996 Impact factor: 3.850
Authors: E Kobayashi; A Okamoto; M Asada; M Okabe; S Nagamura; A Asai; H Saito; K Gomi; T Hirata Journal: Cancer Res Date: 1994-05-01 Impact factor: 12.701
Authors: T Yasuzawa; K Muroi; M Ichimura; I Takahashi; T Ogawa; K Takahashi; H Sano; Y Saitoh Journal: Chem Pharm Bull (Tokyo) Date: 1995-03 Impact factor: 1.645
Authors: Elwood A Mullins; Rongxin Shi; Zachary D Parsons; Philip K Yuen; Sheila S David; Yasuhiro Igarashi; Brandt F Eichman Journal: Nature Date: 2015-10-28 Impact factor: 49.962